Recognise products approved in GHTF countries, says NZ industry - Update
This article was originally published in SRA
The New Zealand medtech industry association, the MTANZ, has called for the introduction of a regulatory system that would involve the unilateral recognition of medical devices that have been approved for marketing in at least one of the five founding members of the Global Harmonization Task Force (ie the US, European Union, Japan, Canada and Australia)1.
You may also be interested in...
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
If Zolgensma gets the thumbs up from the EMA this week, it will likely get formal EU approval within a couple of months.
BMS should find out mid-2020 whether its new MS drug will be approved in the EU.